Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact. Here, Alpharmaxim’s William Hind ...

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the ...

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an ...

Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

The first company to take up residence in Bayer Co.Lab Berlin – initially located on the group's pharma headquarters site in ...

A strategy for women's health in England was published in 2022 under the previous Conservative government, led at the time by ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

Metrics to use to track the 2024 VPAG have been subject to discussions, with reference made to two days where talks were held (17th July and 19th July) in the July VPAG operational review meeting ...